Browse Studies — Arctuva

Phase 1

An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP5…

Non-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal Carcinoma+5 more

Estimated

~$10 – $7,500

AstraZenecaNCT05877599

Phase 1

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

The CD123-CAR T-cell therapy is a new treatment that is being investigated for treatment of AML/myelodysplastic syndrome (MDS), T- or B- acute lymphoblastic le…

AML/MDSB-ALLT-ALL+1 more

Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT04318678

Phase 1

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML

This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed…

AML/MDSAcute Myeloid LeukemiaMyelodysplastic Syndromes

Estimated

~$10 – $6,250

Montefiore Medical CenterNCT05986240